ARS Pharmaceuticals Management
Management criteria checks 1/4
ARS Pharmaceuticals' CEO is Rich Lowenthal, appointed in Nov 2022, has a tenure of 1.5 years. total yearly compensation is $10.04M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 6.15% of the company’s shares, worth $56.40M. The average tenure of the management team and the board of directors is 2.1 years and 2.8 years respectively.
Key information
Rich Lowenthal
Chief executive officer
US$10.0m
Total compensation
| CEO salary percentage | 6.2% |
| CEO tenure | 1.5yrs |
| CEO ownership | 6.2% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$10m | US$620k | -US$54m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$53m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$909k | US$75k | -US$35m |
Compensation vs Market: Rich's total compensation ($USD10.04M) is above average for companies of similar size in the US market ($USD3.42M).
Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.
CEO
Rich Lowenthal (57 yo)
1.5yrs
Tenure
US$10,039,096
Compensation
Mr. Richard E. Lowenthal, also known as Rich, MS, MSEL, MBA, He serves as Director, Chief Executive Officer & President at ARS Pharmaceuticals, Inc. since November 08, 2022. He served as Head of Regulatory...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 1.5yrs | US$10.04m | 6.15% $ 56.4m | |
| Co-Founder & Chief Medical Officer | no data | US$4.79m | 7.13% $ 65.3m | |
| Chief Legal Officer & Secretary | 1.3yrs | US$5.32m | 0.092% $ 844.1k | |
| Co-Founder & Chief Science Officer | no data | no data | 4.35% $ 39.9m | |
| Chief Financial Officer | 2.1yrs | no data | 0.0085% $ 78.0k | |
| Chief Operations Officer | no data | no data | no data | |
| Senior Vice President of Marketing | 2.3yrs | no data | no data | |
| Executive Vice President of Commercial Strategy | 2.3yrs | no data | no data | |
| Chief Commercial Officer | 2.1yrs | US$618.61k | 0% $ 0 | |
| Chief Business Officer & Secretary | 1.5yrs | no data | 0.24% $ 2.2m |
2.1yrs
Average Tenure
54yo
Average Age
Experienced Management: SPRY's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 1.5yrs | US$10.04m | 6.15% $ 56.4m | |
| Independent Director | no data | US$261.30k | 0% $ 0 | |
| Chairman of the Board | no data | US$508.80k | 10.48% $ 96.1m | |
| Director | 3yrs | US$238.80k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$256.30k | no data | |
| Independent Director | 2.8yrs | US$253.80k | no data | |
| Independent Director | 1.5yrs | US$250.05k | 0.016% $ 144.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | no data | US$248.80k | 0.086% $ 787.3k | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.8yrs
Average Tenure
53yo
Average Age
Experienced Board: SPRY's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.